Suppr超能文献

国家毒理学计划关于水合氯醛(化学物质登记号:302-17-0)毒性和代谢研究的技术报告。通过灌胃法给予F344/N大鼠和B6C3F1小鼠。

NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.

作者信息

Beland F A

出版信息

Toxic Rep Ser. 1999 Aug(59):1-66, A1-E7.

Abstract

Chloral hydrate is widely used as a sedative and a hypnotic in pediatric medicine. It is also a byproduct of water chlorination. Chloral hydrate has been shown to be genotoxic in numerous prokaryotic and eukaryotic assay systems including human lymphocytes in vitro. One of its metabolites, trichloroacetic acid, has demonstrated hepatocarcinogenic activity in mice. Trichloroethylene and perchloroethylene, both of which are metabolized to chloral hydrate, have been shown to be carcinogenic in rats and/or mice. Because of this evidence of carcinogenicity and because of the wide-spread use of chloral hydrate, 16- or 17-day range-finding toxicity studies and separate 16- or 17-day metabolism studies were performed in F344/N rats and B6C3F1 mice in preparation for further long-term rodent studies. In addition, in vitro studies of the metabolism and DNA-binding capacity of chloral hydrate and its metabolites were performed. Genetic toxicity studies were conducted in Salmonella typhimurium, cultured Chinese hamster ovary cells, Drosophila melanogaster, and mouse bone marrow cells. For the range-finding studies, groups of eight male and eight female F344/N Nctr BR rats and B6C3F1/Nctr BR (C57BL/6N x C3H/HeN MTV-) mice were administered 0, 50, 100, 200, 400, or 800 mg chloral hydrate per kg body weight in water by gavage 5 days per week for 17 days (rats) or 16 days (mice) for a total of 12 doses. One male rat receiving 800 mg/kg died after five doses. Two 800 mg/kg female rats died after dosing ended but before study termination. One male mouse in each group except the 400 mg/kg group died before the end of the study. Two 800 mg/kg female mice also died before the end of the study. The final mean body weight of 800 mg/kg male rats and the mean body weight gains of 400 and 800 mg/kg males were significantly less than those of the vehicle controls. The mean body weight gains of all groups of dosed male mice were significantly greater than that of the vehicle control group. The only clinical finding in rats and mice attributed to chloral hydrate treatment was light sedation in the 400 mg/kg groups and heavy sedation in the 800 mg/kg groups; sedation subsided within 30 minutes or 3 hours, respectively. The liver weights of 400 mg/kg male mice and 800 mg/kg male and female mice were significantly greater than those of the vehicle control groups. No chemical-related lesions were observed in rats or mice. Male and female rats and mice were administered a single dose of 50 or 200 mg chloral hydrate per kg body weight in water by gavage, or 12 doses of 50 or 200 mg/kg over 17 days (rats) or 16 days (mice). Plasma concentrations of chloral hydrate and its metabolites were determined 15 minutes, 1, 3, 6, and 24 hours, and 2, 4, 8, and 16 days after receiving 1 or 12 doses. Maximum concentrations of chloral hydrate were observed at the initial sampling point of 15 minutes. By 1 hour, the concentrations had dropped substantially, and by 3 hours, chloral hydrate could not be detected in rats or mice. Trichloroacetic acid was the major metabolite detected in the plasma. In rats, the concentrations rose slowly, with the peaks occurring between 1 and 6 hours after treatment. In mice, the peak concentrations were found 1 hour after dosing. The concentrations then slowly decreased such that by 2 days the metabolite could no longer be detected in rats or mice. Trichloroethanol was assayed both as the free alcohol and its glucuronide. In rats, the maximum concentrations of free trichloroethanol occurred at 15 minutes, while the peak concentrations of trichloroethanol glucuronide were found at 1 hour; by 3 hours, concentrations of both metabolites approached background levels. In mice, the maximum concentrations of both metabolites occurred at 15 minutes, and by 1 to 3 hours concentrations approached background levels. The plasma concentrations of chloral hydrate and its metabolites were dose dependent in rats and mice. In mice, plasma concentrations of trichloroacetic acid were significantly higher after a single dose than after 12 doses. None of the metabolic parameters appears to account for species differences that may exist in hepatocarcinogenicity. The data from the study of metabolism and DNA adduct formation indicated that in vitro metabolism of 200 microM to 5 mM chloral hydrate by male B6C3F1 mouse liver microsomes (control microsomes) generated free radical intermediates that resulted in endogenous lipid peroxidation, forming malondialdehyde, formaldehyde, acetaldehyde, acetone, and propionaldehyde. Similar concentrations of trichloroacetic acid and trichloroethanol, the primary metabolites of chloral hydrate, also generated free radicals and induced lipid peroxidation. Lipid peroxidation induced by trichloroacetic acid nearly equaled that induced by chloral hydrate, while that from trichloroethanol was three- to fourfold less. Metabolism of 200 microM to 5 mM chloral hydrate, trichloroacetic acid, and trichloroethanol by liver microsomes of B6C3F1 mice pretreated with pyrazole (pyrazole-induced microsomes) yielded lipid peroxidation products at concentrations two- to threefold greater than those from liver microsomes of untreated mice. Additionally, chloral hydrate-induced lipid peroxidation catalyzed by control and pyrazole-induced microsomes was reduced significantly by 2,4-dichloro-6-phenylphenoxyethylamine, a general cytochrome P450 inhibitor. Human lymphoblastoid transgenic cells expressing cytochrome P(450)2E1 metabolized 200 to 5,000 micrograms/mL chloral hydrate to reactants inducing mutations, whereas the parental cell line was inactive. The malondialdehyde-modified DNA adduct, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)pyrimido[1,2 alpha]purin-10(3H)-one (MDA-MG-1), formed from the metabolism of 1 mM chloral hydrate, trichloroacetic acid, and trichloroethanol by control B6C3F1 mouse liver microsomes, mouse pyrazole-induced microsomes, male F344/N rat liver microsomes, and human liver microsomes in the presence and absence of calf thymus DNA was also determined. When incubated in the absence of calf thymus DNA, the amount of malondialdehyde formed from metabolism by pyrazole-induced mouse microsomes was twice that from rat or human liver microsomes. Amounts of chloral hydrate-induced and trichloroacetic acid-induced lipid peroxidation products formed from metabolism by rat and human liver microsomes were similar, and these quantities were about twice those formed from the metabolism of trichloroethanol. The quantity of MDA-MG-1 formed from the metabolism of chloral hydrate, trichloroacetic acid, and trichloroethanol by mouse, rat, and human liver microsomes exhibited a linear correlation with the quantity of malondialdehyde formed under incubation conditions in the absence of calf thymus DNA. Chloral hydrate was shown to be mutagenic in vitro and in vivo. At doses from 1,000 to 10,000 micrograms/plate, it induced mutations in S. typhimurium strain TA100, with and without S9 activation; an equivocal response was obtained in S. typhimurium strain TA98 in the absence of S9, and no mutagenicity was detected with strain TA1535 or TA1537. Chloral hydrate at doses from 1,700 to 5,000 micrograms/mL induced sister chromatid exchanges; at doses from 1,000 to 3,000 micrograms/mL, chromosomal aberrations were induced in cultured Chinese hamster ovary cells, with and without S9. Results of a sex-linked recessive lethal test in D. melanogaster were unclear; administration of chloral hydrate by feeding produced an inconclusive increase in recessive lethal mutations, results of the injection experiment were negative. An in vivo mouse bone marrow micronucleus test with chloral hydrate at doses from 125 to 500 mg/kg gave a positive dose trend. In summary, due to the absence of chloral hydrate-induced histopathologic lesions in rats and mice, no-observed-adverse-effect levels (NOAELs) were based on body weights of rats and liver weights of mice. The NOAELs for rats and mice were 200 mg/kg. Chloral hydrate was rapidly metabolized by rats and mice, with trichloroacetic acid occurring as the major metabolite. Peak concentrations of trichloroacetic acid occurred more quickly in mice. Plasma concentrations of chloral hydrate were dose dependent, but metabolic rates were unaffected by dose or sex. Chloral hydrate was mutagenic in vitro and in vivo. Metabolism of chloral hydrate and its metabolites produced free radicals that resulted in lipid peroxidation in liver microsomes of mice, rats, and humans. Induction of cytochrome P(450)2E1 by pyrazole increased the concentrations of lipid peroxidation products; inhibition of cytochrome P(450)2E1 by 2,4-dinitrophenylhydrazine reduced these concentrations. Metabolism of chloral hydrate and its metabolites by mouse, rat, and human liver microsomes formed malondialdehyde, and in the presence of calf thymus DNA formed the DNA adduct MDA-MG-1.

摘要

水合氯醛在儿科医学中被广泛用作镇静剂和催眠药。它也是水氯化的副产物。在包括人淋巴细胞体外培养在内的众多原核和真核检测系统中,水合氯醛已被证明具有遗传毒性。其代谢产物之一三氯乙酸已在小鼠中表现出肝癌致癌活性。三氯乙烯和全氯乙烯都代谢为水合氯醛,已被证明在大鼠和/或小鼠中具有致癌性。由于有这种致癌性证据以及水合氯醛的广泛使用,为准备进一步的长期啮齿动物研究,在F344/N大鼠和B6C3F1小鼠中进行了16或17天的预试验毒性研究以及单独的16或17天代谢研究。此外,还进行了水合氯醛及其代谢产物的代谢和DNA结合能力的体外研究。在鼠伤寒沙门氏菌、培养的中国仓鼠卵巢细胞、黑腹果蝇和小鼠骨髓细胞中进行了遗传毒性研究。在预试验研究中,每组八只雄性和八只雌性F344/N Nctr BR大鼠和B6C3F1/Nctr BR(C57BL/6N×C3H/HeN MTV-)小鼠,每周5天经口灌胃给予0、50、100、200、400或800mg/kg体重的水合氯醛,持续17天(大鼠)或16天(小鼠),共12剂。一只接受800mg/kg的雄性大鼠在五剂后死亡。两只800mg/kg的雌性大鼠在给药结束后但在研究终止前死亡。除400mg/kg组外,每组一只雄性小鼠在研究结束前死亡。两只800mg/kg的雌性小鼠也在研究结束前死亡。800mg/kg雄性大鼠的最终平均体重以及400和800mg/kg雄性大鼠的平均体重增加量显著低于溶剂对照组。所有给药雄性小鼠组的平均体重增加量均显著高于溶剂对照组。在大鼠和小鼠中,归因于水合氯醛治疗的唯一临床发现是400mg/kg组出现轻度镇静,800mg/kg组出现重度镇静;镇静分别在30分钟或3小时内消退。400mg/kg雄性小鼠以及800mg/kg雄性和雌性小鼠的肝脏重量显著高于溶剂对照组。在大鼠或小鼠中未观察到与化学物质相关的病变。雄性和雌性大鼠和小鼠经口灌胃给予单剂量50或200mg/kg体重的水合氯醛,或在17天(大鼠)或16天(小鼠)内给予12剂50或200mg/kg。在接受1或12剂后15分钟、1、3、6和24小时以及2、4、8和16天测定水合氯醛及其代谢产物的血浆浓度。在15分钟的初始采样点观察到水合氯醛的最大浓度。到1小时时,浓度大幅下降,到3小时时,在大鼠或小鼠中无法检测到水合氯醛。三氯乙酸是血浆中检测到的主要代谢产物。在大鼠中,浓度缓慢上升,在治疗后1至6小时出现峰值。在小鼠中,给药后1小时发现峰值浓度。然后浓度缓慢下降,以至于到2天时,在大鼠或小鼠中无法再检测到该代谢产物。三氯乙醇以游离醇及其葡糖醛酸苷形式进行测定。在大鼠中,游离三氯乙醇的最大浓度出现在15分钟,而三氯乙醇葡糖醛酸苷的峰值浓度出现在1小时;到3小时时,两种代谢产物的浓度接近背景水平。在小鼠中,两种代谢产物的最大浓度均出现在15分钟,到1至3小时时浓度接近背景水平。大鼠和小鼠中水合氯醛及其代谢产物的血浆浓度呈剂量依赖性。在小鼠中,单剂量后三氯乙酸的血浆浓度显著高于12剂后。似乎没有任何代谢参数可以解释可能存在的肝癌致癌性物种差异。代谢和DNA加合物形成研究的数据表明,雄性B6C3F1小鼠肝微粒体(对照微粒体)将200μM至5mM水合氯醛体外代谢产生自由基中间体,导致内源性脂质过氧化,形成丙二醛、甲醛、乙醛、丙酮和丙醛。类似浓度的水合氯醛主要代谢产物三氯乙酸和三氯乙醇也产生自由基并诱导脂质过氧化。三氯乙酸诱导的脂质过氧化几乎与水合氯醛诱导的脂质过氧化相等,而三氯乙醇诱导的脂质过氧化则少三至四倍。用吡唑预处理的B6C3F1小鼠肝微粒体(吡唑诱导微粒体)将200μM至5mM水合氯醛、三氯乙酸和三氯乙醇代谢产生的脂质过氧化产物浓度比未处理小鼠的肝微粒体高两至三倍。此外,一种通用的细胞色素P450抑制剂2,4 - 二氯 - 6 - 苯氧基乙胺显著降低了对照和吡唑诱导微粒体催化的水合氯醛诱导的脂质过氧化。表达细胞色素P(450)2E1的人淋巴母细胞转基因细胞将200至5000μg/mL水合氯醛代谢为诱导突变的反应物,而亲本细胞系无活性。由对照B6C3F1小鼠肝微粒体、小鼠吡唑诱导微粒体、雄性F344/N大鼠肝微粒体和人肝微粒体在有和没有小牛胸腺DNA存在的情况下将1mM水合氯醛、三氯乙酸和三氯乙醇代谢形成的丙二醛修饰的DNA加合物3 - (2 - 脱氧 - β - D - 赤藓糖基)嘧啶并[1,2α]嘌呤 - 10(3H) - 酮(MDA - MG - 1)也进行了测定。在没有小牛胸腺DNA的情况下孵育时,吡唑诱导的小鼠微粒体代谢形成的丙二醛量是大鼠或人肝微粒体的两倍。大鼠和人肝微粒体代谢形成的水合氯醛诱导和三氯乙酸诱导的脂质过氧化产物量相似,这些量约为三氯乙醇代谢形成量的两倍。小鼠、大鼠和人肝微粒体将水合氯醛、三氯乙酸和三氯乙醇代谢形成的MDA - MG - 1量与在没有小牛胸腺DNA的孵育条件下形成的丙二醛量呈线性相关。水合氯醛在体外和体内均被证明具有致突变性。在1000至10000μg/平板的剂量下,它在有和没有S9激活的情况下诱导鼠伤寒沙门氏菌TA100菌株发生突变;在没有S9的情况下,鼠伤寒沙门氏菌TA98菌株获得了模棱两可的反应,而TA1535或TA1537菌株未检测到致突变性。水合氯醛在1700至5000μg/mL的剂量下诱导姐妹染色单体交换;在1000至3000μg/mL的剂量下,在有和没有S9的情况下,在培养的中国仓鼠卵巢细胞中诱导染色体畸变。黑腹果蝇的性连锁隐性致死试验结果不明确;通过喂食给予水合氯醛导致隐性致死突变的增加不确定,注射实验结果为阴性。水合氯醛在125至500mg/kg剂量下进行的体内小鼠骨髓微核试验呈现出阳性剂量趋势。总之,由于在大鼠和小鼠中未出现水合氯醛诱导的组织病理学病变,未观察到有害作用水平(NOAELs)基于大鼠的体重和小鼠的肝脏重量确定。大鼠和小鼠的NOAELs均为200mg/kg。大鼠和小鼠能快速代谢水合氯醛,三氯乙酸是主要代谢产物。小鼠中三氯乙酸的峰值浓度出现得更快。水合氯醛的血浆浓度呈剂量依赖性,但代谢率不受剂量或性别的影响。水合氯醛在体外和体内均具有致突变性。水合氯醛及其代谢产物的代谢产生自由基,导致小鼠、大鼠和人类肝微粒体中的脂质过氧化。吡唑诱导细胞色素P(450)2E1增加脂质过氧化产物的浓度;2,4 - 二硝基苯肼抑制细胞色素P(450)2E1降低这些浓度。小鼠、大鼠和人肝微粒体将水合氯醛及其代谢产物代谢形成丙二醛,并在有小牛胸腺DNA的情况下形成DNA加合物MDA - MG - 1。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验